USANA Health Sciences, Inc. reiterated consolidated earnings guidance for the fiscal year 2024. For the period, the company expects net sales of $850 million - $920 million and Diluted EPS of $2.40 - $3.00.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.48 USD | -0.05% |
|
+2.02% | -14.42% |
07/05 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
01/05 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.42% | 867M | |
+13.80% | 8.09B | |
+0.47% | 7.39B | |
-8.08% | 5.37B | |
-7.40% | 3.63B | |
-19.73% | 3.27B | |
-12.00% | 1.19B | |
-26.28% | 1.13B | |
+0.89% | 879M | |
-12.89% | 846M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2024